Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Teknolohiya·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Teknolohiya·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% tsansa
Polymarket

$11,264 Vol.

13% tsansa
Polymarket

$11,264 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron have operated under a non-exclusive material transfer and evaluation agreement since October 2024, using SmartDepot’s ultrasonic spray-drying microsphere technology to test sustained-release formulations for peptide candidates, but no commercial licensing deal has been announced. Recent July 2026 updates confirm the research continues across multiple assets without progress toward binding terms, while Lilly’s separate pivot toward oral obesity programs and the two-year timeline since the initial MTA reduce the likelihood of a full license by early October. Traders view the 87.5% “No” odds as reflecting typical extended negotiation cycles for such platform deals, though a surprise announcement or positive feasibility data could still shift sentiment before the deadline.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264
Petsa ng Pagtatapos
Oct 7, 2026
Binuksan ang Market
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron have operated under a non-exclusive material transfer and evaluation agreement since October 2024, using SmartDepot’s ultrasonic spray-drying microsphere technology to test sustained-release formulations for peptide candidates, but no commercial licensing deal has been announced. Recent July 2026 updates confirm the research continues across multiple assets without progress toward binding terms, while Lilly’s separate pivot toward oral obesity programs and the two-year timeline since the initial MTA reduce the likelihood of a full license by early October. Traders view the 87.5% “No” odds as reflecting typical extended negotiation cycles for such platform deals, though a surprise announcement or positive feasibility data could still shift sentiment before the deadline.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264
Petsa ng Pagtatapos
Oct 7, 2026
Binuksan ang Market
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Kaugnay

icon for FDA approves Retatrutide this year?

FDA approves Retatrutide this year?

3%
icon for ChatGPT outage on August 12, 2026?

ChatGPT outage on August 12, 2026?

38%
icon for ChatGPT Outage by August 31, 2026?

ChatGPT Outage by August 31, 2026?

69%

Mag-ingat sa mga external link.

Mga Madalas na Tanong

Ang "Eli Lilly licenses Peptron’s SmartDepot by October 7?" ay isang prediction market sa Polymarket kung saan bumibili at nagbebenta ang mga trader ng "Yes" o "No" shares batay sa kung naniniwala silang mangyayari ang event na ito. Ang kasalukuyang crowd-sourced probability ay 13% para sa "Yes." Halimbawa, kung ang "Yes" ay naka-presyo sa 13¢, ang market ay kolektibong nagtatakda ng 13% na tsansa na mangyayari ang event na ito. Patuloy na nagbabago ang mga odds na ito habang tumutugon ang mga trader sa mga bagong development at impormasyon. Ang mga shares sa tamang outcome ay mare-redeem sa $1 bawat isa sa market resolution.

Sa ngayon, ang "Eli Lilly licenses Peptron’s SmartDepot by October 7?" ay naka-generate ng $11.3K sa kabuuang trading volume mula nang ilunsad ang market noong May 5, 2026. Ang antas na ito ng trading activity ay sumasalamin sa malakas na engagement mula sa Polymarket community at tumutulong na matiyak na ang kasalukuyang odds ay sinusuportahan ng malawak na pool ng mga market participant. Maaari mong subaybayan ang live price movements at mag-trade sa anumang outcome nang direkta sa pahinang ito.

Para mag-trade sa "Eli Lilly licenses Peptron’s SmartDepot by October 7?," piliin lang kung naniniwala ka na ang sagot ay "Yes" o "No." Ang bawat panig ay may kasalukuyang presyo na sumasalamin sa implied probability ng market. Ilagay ang iyong halaga at i-click ang "Trade." Kung bibili ka ng "Yes" shares at na-resolve ang outcome bilang "Yes," nagbabayad ang bawat share ng $1. Kung na-resolve bilang "No," ang iyong "Yes" shares ay nagkakahalaga ng $0. Maaari ka ring magbenta ng iyong shares anumang oras bago ang resolution kung gusto mong i-lock in ang kita o bawasan ang pagkalugi.

Ang kasalukuyang probability para sa "Eli Lilly licenses Peptron’s SmartDepot by October 7?" ay 13% para sa "Yes." Ibig sabihin nito na kasalukuyang naniniwala ang Polymarket crowd na may 13% tsansa na mangyayari ang event na ito. Nag-a-update ang mga odds na ito sa real-time batay sa actual trades, na nagbibigay ng patuloy na ina-update na signal kung ano ang inaasahan ng market na mangyayari.

Ang mga resolution rules para sa "Eli Lilly licenses Peptron’s SmartDepot by October 7?" ay tiyak na nagde-define kung ano ang kailangang mangyari para sa bawat outcome na maideklara bilang panalo — kasama ang mga opisyal na data source na ginagamit para matukoy ang resulta. Maaari mong i-review ang kumpletong resolution criteria sa "Rules" section sa pahinang ito sa itaas ng mga komento. Inirerekomenda namin na basahin nang mabuti ang mga patakaran bago mag-trade, dahil tinutukoy nila ang mga tiyak na kondisyon, edge cases, at mga source na namamahala kung paano nise-settle ang market na ito.